Biocon: Japan Biosimilar Glargine Nod To Open Other Doors
This article was originally published in PharmAsia News
Executive Summary
India's largest biopharmaceutical company, Biocon, has reported quarterly net profit rocketed nearly 80% thanks to exceptional income, and says Japan's regulatory nod for its insulin glargine should help “fast-track” approvals of the biosimilar in both emerging markets and advanced economies.
You may also be interested in...
India's Biosimilar Norms: Patient Safety Debate Boils Over
A recent panel discussion in India brought to the fore simmering tensions over the country's guidelines on biosimilars, with some panelists suggesting the guidelines compromise on patient safety while other experts sought to tone down any alarmist conclusions.
India's Biosimilar Norms: Patient Safety Debate Boils Over
A recent panel discussion in India brought to the fore simmering tensions over the country's guidelines on biosimilars, with some panelists suggesting the guidelines compromise on patient safety while other experts sought to tone down any alarmist conclusions.
Share Fillip As Indian Pharma Crests US Regulatory Hump
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.